InsB (9-23)
Based on 1 Customer Validation
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes. InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.98%
- CAS 番号: 163364-16-7
- 分子式: C72H116N20O22S1
- 分子量:1645.90
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
|
MHC II |
InsB (9-23) (2.5 μM; 48 h) stimulates IFN-γ secretion by the insB:11-23-specific T1D#3 C8 human T cell clone from a type 1 diabetes patient when presented by HLA-DQ8-expressing HEK293 APCs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:insB:11-23-specific human T cell clone (T1D#3 C8) and HLA-DQ8-cis- or DQ8-trans-expressing HEK293 antigen-presenting cells
-
Concentration:2.5 μM
-
Incubation Time:48 h
-
Result:Stimulated IFN-γ secretion by the insB:11-23-specific human T cell clone, with lower activity observed relative to the hyperactive InsB:9-23R22E peptide variant.
InsB (9-23) (100 μg; s.c.; once; 1 day after T-cell transfer) combined with adoptive transfer of InsB (9-23)-specific TCR-engineered human CD4+ T cells induces diabetes in 60% of streptozotocin-conditioned HLA-DQ8-Tg hu-mice, accompanied by pancreatic islet destruction and human T-cell infiltration[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HLA-DQ8-transgenic NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (6-12 weeks old, type 1 diabetes model via low-dose streptozotocin conditioning + adoptive transfer of autologous InsB (9-23)-specific TCR-engineered human CD4+ T cells + immunization with InsB (9-23))[3]
-
Dosage:100 μg
-
Administration:s.c.; once (1 day after T-cell transfer)
-
Result:Induced hyperglycemia and diabetes in approximately 60% of mice by 28 days post-T-cell infusion.
Caused severe destruction of pancreatic islets and human CD3+ T-cell infiltration in diabetic mice.
Enabled detection of infused GFP+ InsB (9-23)-TCR-engineered CD4+ T cells in peripheral blood for at least 6 days, in spleen and liver for at least 3 weeks, in bone marrow for at least 5 weeks, and in pancreatic islets by 11 days post-infusion.
化学情報
-
CAS 番号 163364-16-7
-
性状 Solid
-
分子量 1645.90
-
分子式 C72H116N20O22S1
-
Color White to off-white
-
別名
Insulin B chain (9-23)
-
シーケンスの短縮
SHLVEALYLVCGERG
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
Acetic acid : 4 mg/mL (2.43 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wenzlau JM, et al. Insulin B-chain hybrid peptides are agonists for T cells reactive to insulin B:9-23 in autoimmune diabetes. Front Immunol. 2022;13:926650. Published 2022 Aug 10. [Content Brief]
[2]. Girdhar K, et al. A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes. Proc Natl Acad Sci U S A. 2022;119(31):e2120028119. [Content Brief]
[3]. Tan S, et al. Type 1 diabetes induction in humanized mice. Proc Natl Acad Sci U S A. 2017;114(41):10954-10959. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Acetic acid | 1 mM | 0.6076 mL | 3.0379 mL | 6.0757 mL | 15.1893 mL |